Want to create an interactive transcript for this episode?
Podcast: CME
Episode: FCS and SHTG: Are We Meeting the Need?
Description:
Guest: Ira J. Goldberg, MD
Guest: Kausik Ray, MBChB, MD, MPhil
Guest: Christie Ballantyne, MD
Patients with familial chylomicronemia (FCS) and severe hypertriglyceridemia (SHTG) suffer from multiple complications, the most severe being acute pancreatitis. Current therapeutic agents, which include fibrates, omega-3 fatty acids, statins, and niacin, are generally ineffective. There are new developments with investigational siRNA therapeutics that silence APOC3, a key regulator of triglycerides and triglyceride-rich lipoproteins. Recent presentations have highlighted outcomes of trials evaluating APOC3 siRNA therapeutics in patients with FCS or SHTG. Drs. Ray, Goldberg, and Ballantyne discuss the findings of these trials...